{"id":83,"date":"2013-10-17T18:56:00","date_gmt":"2013-10-17T22:56:00","guid":{"rendered":"http:\/\/blog.cmhughesmd.com\/?p=83"},"modified":"2013-10-17T18:56:00","modified_gmt":"2013-10-17T22:56:00","slug":"the-myth-of-the-medical-device-tax-nytimes-com","status":"publish","type":"post","link":"http:\/\/blog.cmhughesmd.com\/?p=83","title":{"rendered":"The Myth of the Medical-Device Tax &#8211; NYTimes.com"},"content":{"rendered":"<p>&#160;<\/p>\n<blockquote>\n<p>Not only can the medical-device industry easily afford the tax without compromising innovation, but the industry\u2019s enormous profits are a result of anticompetitive practices that themselves drive up medical-device costs unnecessarily. The tax is a distraction from reforms to the industry that are urgently needed to lower health care costs. <\/p>\n<p>The medical-device industry faces virtually no price competition. Because of confidentiality agreements that manufacturers require hospitals to sign, the prices of the devices are cloaked in secrecy. This lack of transparency impedes hospitals from sharing price information and thus knowing whether they are getting a good deal. <\/p>\n<p>Even worse, manufacturers often maintain personal relationships (sometimes involving financial payments like consulting fees) with physicians who choose the medical devices that their hospitals purchase, creating a conflict of interest. Physicians often don\u2019t even know the costs of the devices, and individual physicians often choose devices on their own, which weakens a hospital\u2019s ability to bargain for volume discounts. <\/p>\n<p>Such anticompetitive practices help generate a wide variation in the prices of medical devices \u2014 and contribute to higher prices in general. For example, the Government Accountability Office found that prices for cardiac implantable medical devices in the United States vary by several thousand dollars. And even the lowest-priced devices in the United States are expensive compared with those in other developed countries. According to the consulting firm McKinsey &amp; Company, the United States spends about 50 percent more than expected on the top five medical devices, compared with Europe and Japan. McKinsey calculates that this amounts to $26 billion in excessive spending each year. <a href=\"http:\/\/topics.nytimes.com\/top\/news\/health\/diseasesconditionsandhealthtopics\/medicare\/index.html?inline=nyt-classifier\">Medicare<\/a>, private health insurers and patients end up paying these inflated prices. <\/p>\n<p>Excessive prices fuel enormous profits \u2014 profits that dwarf both the medical-device tax and the industry\u2019s investments in research and development. Consider the device division of Johnson &amp; Johnson, which in 2012 had an operating profit of $7.2 billion. By the company\u2019s own estimate, the device tax would amount to at most $300 million, and its investment in research and development amounts to only $1.7 billion. <\/p>\n<\/blockquote>\n<p><a href=\"http:\/\/www.nytimes.com\/2013\/10\/17\/opinion\/the-myth-of-the-medical-device-tax.html?emc=edit_tnt_20131016&amp;tntemail0=y&amp;_r=0\">The Myth of the Medical-Device Tax &#8211; NYTimes.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#160; Not only can the medical-device industry easily afford the tax without compromising innovation, but the industry\u2019s enormous profits are a result of anticompetitive practices that themselves drive up medical-device &hellip; <a href=\"http:\/\/blog.cmhughesmd.com\/?p=83\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;The Myth of the Medical-Device Tax &#8211; NYTimes.com&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"sfsi_plus_gutenberg_text_before_share":"","sfsi_plus_gutenberg_show_text_before_share":"","sfsi_plus_gutenberg_icon_type":"","sfsi_plus_gutenberg_icon_alignemt":"","sfsi_plus_gutenburg_max_per_row":"","footnotes":""},"categories":[19,43,60],"tags":[],"class_list":["post-83","post","type-post","status-publish","format-standard","hentry","category-contrarian-economics","category-pharmaceutical-industry","category-us-world-health-care-policy"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=\/wp\/v2\/posts\/83","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=83"}],"version-history":[{"count":0,"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=\/wp\/v2\/posts\/83\/revisions"}],"wp:attachment":[{"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=83"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=83"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blog.cmhughesmd.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=83"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}